AZD1480

製品コードS2162

AZD1480化学構造

分子量(MW):348.77

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.

サイズ 価格(税別)  
JPY 21580.00
JPY 16600.00
JPY 28220.00
JPY 94620.00

カスタマーフィードバック(4)

  • bDNA analysis showing that the JAK1/2 inhibitors CYT387, AZD1480 and Baricitinib positively regulate UCP1 expression in PSC-WA. Values are mean ± s.d. of n = three biological replicates and differences from DMSO are significant for * P < 0.005. P values were calculated using the two-tailed paired Student's t-test.

    Nat Cell Biol, 2015, 17(1): 57-67. AZD1480 purchased from Selleck.

    Adipocytes were pre-infected with pAd-Foxc2 or si-Foxc2, and incubated with AZD1480 or not. Figures show protein levels of leptin, IL-6 and TNFα in adipocytes.

    Int J Obes, 2018, 42(2):252-259. AZD1480 purchased from Selleck.

  • A431 cells were treated with ALA-PDT alone or pretreated with 1μM AZD1480 for 1h or pretreated with 1ng/ml OSM for 10 minutes and the protein expression of Bcl-2 and Bax were analyzed by Western Blot.

    Photodiagnosis Photodyn Ther, 2016, 14:119-27. AZD1480 purchased from Selleck.

    HEL cells were treated for 3 hours with the indicated concentrations of AZD1480. AZD1480 inhibits Jak2-V617F mediated signal transduction at micromolar  concentrations in intact cells.

     

     

    M.Sc. Karoline Gaebler and Dr. Claude Haan of Université du Luxembour. AZD1480 purchased from Selleck.

製品安全説明書

JAK阻害剤の選択性比較

生物活性

製品説明 AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.
ターゲット
JAK2 [1]
(Cell-free assay)
0.26 nM
体外試験

5μM AZD1480 induces G2/M arrest and cell death by inhibiting Aurora kinases. [1] AZD1480 is a potent JAK2 inhibitor that can suppress growth, survival, as well as FGFR3 and STAT3 signaling and downstream targets including Cyclin D2 in human multiple myeloma cells. At low micromolar concentrations, AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. [2]AZD1480 effectively blocks constitutive and stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both human and murine glioma cells, and leads to a decrease in cell proliferation and induction of apoptosis. [3]AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase, and that it is capable of inhibiting STAT3 phosphorylation and tumor growth in a STAT3-dependent manner. AZD1480 inhibits tumor angiogenesis and metastasis in part by affecting the tumor microenvironment. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SW620 NEnXd2tHfW6ldHnvckBCe3OjeR?= MWq1JO69VQ>? NVy2UIk6PDhiaB?= M3H4dmROW09? Mo\qZoxw[2u|IFrBT|IwW1SDVEOgd4lodmGuaX7n NFn3WWUzPTl3NEm3OC=>
LoVo  NFLNclBHfW6ldHnvckBCe3OjeR?= MoLIOUDPxE1? MYK0PEBp MUfEUXNQ MXPicI9kc3NiSlHLNk9UXEGWMzDzbYdv[Wyrbne= MV:yOVk2PDl5NB?=
HN5 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnYUGZQPzJiaB?= NIH0R4lGSzVyPUOuPFEhyrFiMT65PUDPxE1? M{jVPVI2QDFyMEGw
Cal33 M{\r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2myWFczKGh? NHexXlNGSzVyPUOuN|chyrFiMD63OUDPxE1? M3T1OFI2QDFyMEGw
UM-22B NXfiUJRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofLO|IhcA>? NWfhNmYzTUN3ME2yMlY3KMLzIECuNlQh|ryP MV2yOVgyODBzMB?=
686LN NHr6SHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH6O|IhcA>? NV\jUnhETUN3ME2yMlA2KMLzIEGuN|Mh|ryP NV;rem03OjV6MUCwNVA>
UM SCC-1 NVXDZ|FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NkBp M{fwcmVEPTB;MT62O{DDuSByLkSyJO69VQ>? NGPGOGgzPThzMECxNC=>
UM-22A M3zXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XvclczKGh? NW[xUnR{TUN3ME2xMlMzKMLzIECuN|kh|ryP MWCyOVgyODBzMB?=
OSC19 NX:2R2liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVe3NkBp NV;NVoVXTUN3ME2xMlI3KMLzIECuNlAh|ryP NGG1dnozPThzMECxNC=>
PCI-52 M1zYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NkBp NHjJdnFGSzVyPUGuNFAhyrFiMD6wPUDPxE1? M4PiVlI2QDFyMEGw
PCI-15B MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\LflczKGh? M4HDTWVEPTB;MD65PUDDuSBzLke0JO69VQ>? NHXRVVkzPThzMECxNC=>
UMSCC-1 NVz0TnVHTnWwY4Tpc44hSXO|YYm= MYSwMlAxODVvMT62JO69VQ>? M1zp[VI1KGh? NX3QRms3[WK{b3fheIV{KEmOLUdihLNqdmS3Y3XkJJVxNXKnZ4XsZZRqd25ib3[gdHNVSVR|VInyO|A2yqCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnPiNlU5OTByMUC=
Cal33 MoiwSpVv[3Srb36gRZN{[Xl? M{DYe|AvODByNT2zMlgh|ryP MlT2NlQhcA>? MUDhZpJw\2G2ZYOgTWwuPuLCk3nu[JVk\WRidYCtdoVofWyjdHnvckBw\iCyU2TBWFNVgXJ5MEZCpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MX[yOVgyODBzMB?=
HH5 NGDmcGdHfW6ldHnvckBCe3OjeR?= NYf5XJdCOC5yMEC1MVMvQCEQvF2= NHzPb28zPCCq NE[1SHRi[nKxZ3H0[ZMhUUxvNvMAl4lv\HWlZXSgeZAuemWpdXzheIlwdiCxZjDwV3RCXDOWeYK3NFXDqGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{fOelI2QDFyMEGw
UM-22A M4PpbGZ2dmO2aX;uJGF{e2G7 NIPndFYxNjByMEWtNU43KM7:TR?= MYqyOEBp MWThZpJw\2G2ZYOgTWwuPuLCk3nu[JVk\WRidYCtdoVofWyjdHnvckBw\iCyU2TBWFNVgXJ5MEZCpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MV2yOVgyODBzMB?=
A1847 M3y1UWZ2dmO2aX;uJGF{e2G7 MknhNE4xPS1zMDFOwG0> M2TpdlI1KGh? NInDbZdFVVORwrC= NW\uR|RqemWmdXPld{BxcG:|cHjvdplt[XSnZDDTWGFVOyCuZY\lcJM> M4XhbFI2PjR4MEG1
OVCAR-5 NXuxNGxSTnWwY4Tpc44hSXO|YYm= MkTaNE4xPS1zMDFOwG0> NXHmS5VsOjRiaB?= M3nxd2ROW00EoB?= MWTy[YR2[2W|IIDoc5NxcG:{eXzheIVlKFOWQWSzJIxmfmWucx?= M{m1elI2PjR4MEG1
OVCAR-8 NUjUZ3ZJTnWwY4Tpc44hSXO|YYm= M1LuZ|AvODVvMUCg{txO NEW3OGYzPCCq M4ftbGROW00EoB?= NFG2N5Nz\WS3Y3XzJJBpd3OyaH;yfYxifGWmIGPURXQ{KGyndnXsdy=> MofzNlU3PDZyMUW=
MOVCAR-5447 MnjYSpVv[3Srb36gRZN{[Xl? NHTSZXcxNjB3LUGwJO69VQ>? NGXqUFEzPCCq NHL4enZFVVORwrC= NFnnWmRz\WS3Y3XzJJBpd3OyaH;yfYxifGWmIGPURXQ{KGyndnXsdy=> MmPsNlU3PDZyMUW=
MOVCAR-5009 M4PwZ2Z2dmO2aX;uJGF{e2G7 NIXScWsxNjB3LUGwJO69VQ>? MmHLNlQhcA>? M{PWcGROW00EoB?= M3npepJm\HWlZYOgdIhwe3Cqb4L5cIF1\WRiU2TBWFMhdGW4ZXzz NXf5dHhbOjV4NE[wNVU>
A1847 NX2xR3R{S2WubDDWbYFjcWyrdImgRZN{[Xl? M4fP[|AvODVvMUCg{txO M1n0SVczKGh? NUHZUJR3TE2VTx?= M1\iTpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDVizszN M3rXUlI2PjR4MEG1
OVCAR-5 NXPTR3ZqS2WubDDWbYFjcWyrdImgRZN{[Xl? NIDnZXExNjB3LUGwJO69VQ>? NH;heI04OiCq MoOwSG1UVw>? MmXydoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhPSEQvF2= Mke3NlU3PDZyMUW=
OVCAR-8  M4nORmNmdGxiVnnhZoltcXS7IFHzd4F6 MXWwMlA2NTFyIN88US=> NUPmOGpXPzJiaB?= MUDEUXNQ M{XXSZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDVizszN NXvQT|k2OjV4NE[wNVU>
OVCAR-5  M3zU[mFxd3C2b4Ppd{BCe3OjeR?= M2HtO|AvPS9zL{Wg{txO NHzhfYc1QCCq M3roZmROW09? NUnKZ25pcW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI9{cXNiYYSgbIlocCClb37j[ZJvfHKjdHnvci=> NYm4OHBGOjV4NE[wNVU>
OVCAR-8  M{DaU2Fxd3C2b4Ppd{BCe3OjeR?= MWqwMlUwOS93IN88US=> Mn\YOFghcA>? M2fPR2ROW09? NWrhepA5cW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI9{cXNiYYSgbIlocCClb37j[ZJvfHKjdHnvci=> MXKyOVY1PjBzNR?=
AKRSL NVHsWHgxS2WubDDWbYFjcWyrdImgRZN{[Xl? NHPFfVQ4OiCq M3nTRWlEPTExvK6xNEDPxE1? NF;NW|YzPTVyNE[zOS=>
PALJDL MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlP2O|IhcA>? M{[wc2lEPTB;Mj60JO69VQ>? M1jldFI2PTB2NkO1
MO4 M2i5NWZ2dmO2aX;uJGF{e2G7 M3r0cFAvPS9zL{Wg{txO NV;WT5VjPiCq NI\yUG5qdmirYnn0d{BRNVOWQWSzJIV5eHKnc4Ppc47DqA>? Mk\hNlUyPDl3M{W=
DU145  MX3GeY5kfGmxbjDBd5NigQ>? NVLUW5NTOC1{MECgcm0> MnniNUBpyqB? M17VW5N2eHC{ZYPz[ZMhUUxvNj3hZ5RqfmG2ZXSgV5RifDNiYX7kJGVTUzFxMjDzbYdv[Wyrbne= NYrQd5JPOjR3N{e5OFI>
DU145  NUfYc3lLTnWwY4Tpc44hSXO|YYm= MmPZPFAxKG6P NWLidFFwPzJiaB?= NXnBN|BTe3WycILld5NmeyCLTD22MYlv\HWlZXSgcYloemG2b4L5 NXrJdFlLOjR3N{e5OFI>
CWR22Rv1 M1e1V2Z2dmO2aX;uJGF{e2G7 NGjJbXM5ODBibl2= M{HVPVczKGh? NHLiOZR{fXCycnXzd4V{KEmOLU[tbY5lfWOnZDDtbYdz[XSxcom= NX7I[ItGOjR3N{e5OFI>
N592 NVTpfVQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj2[GMzUUN3ME2wMlg1KM7:TR?= MkLDNlQyPTh5MEG=
H82 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnYSmdKSzVyPUGuN|ch|ryP M2XpNlI1OTV6N{Cx
GLC4 NFnlOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrnTWM2OD1zLke5JO69VQ>? M{[0U|I1OTV6N{Cx
H526 MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\5W2E4UUN3ME2zMlA5KM7:TR?= NYOxXoF6OjRzNUi3NFE>
H1173 NWXXdmpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDufpp[UUN3ME2yMlM6KM7:TR?= M3LjSVI1OTV6N{Cx
DMS114 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPv[HB7UUN3ME2wMlc{KM7:TR?= M{fVV|I1OTV6N{Cx
NCI-N592 M3f0XmZ2dmO2aX;uJGF{e2G7 MUWwMlMwOS9|IN88US=> M4DpV|I1KGh? NH7vW2xqdmS3Y3XzJGczN01iY3XscEBkgWOuZTDhdpJme3R? NYXaVVQ3OjRzNUi3NFE>
GLC4 NWjNVIlETnWwY4Tpc44hSXO|YYm= NYPXS2lTOC5|L{GvN{DPxE1? MYWyOEBp MmHDbY5lfWOnczDHNk9OKGOnbHygZ5lkdGViYYLy[ZN1 MYCyOFE2QDdyMR?=
NCI-H82 NInyUVVHfW6ldHnvckBCe3OjeR?= M3HINFAvOy9zL{Og{txO MXSyOEBp NEjs[5hqdmS3Y3XzJGczN01iY3XscEBkgWOuZTDhdpJme3R? MWKyOFE2QDdyMR?=
NCI-N592 M13XSWFxd3C2b4Ppd{BCe3OjeR?= M4P3O|AvOy9zL{Og{txO Mn7OOFghcA>? MoqwbY5kemWjc3XzJJRp\SCuZY\lcEBw\iClbHXheoVlNUOjc4Dhd4UhOw>? MWOyOFE2QDdyMR?=
GLC4 NYH3fJlXSXCxcITvd4l{KEG|c3H5 NF;JRoQxNjNxMT:zJO69VQ>? NVj5NHJUPDhiaB?= NELaTI9qdmO{ZXHz[ZMhfGinIHzleoVtKG:oIHPs[YF3\WRvQ3HzdIF{\SB| NXLCXFVmOjRzNUi3NFE>
NCI-H82 MnrMRZBweHSxc3nzJGF{e2G7 MlrrNE4{NzFxMzFOwG0> M1y0W|Q5KGh? NELa[4ZqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIHPs[YF3\WRvQ3HzdIF{\SB| MWSyOFE2QDdyMR?=
CWR22Rv1  NUDpVnJISXCxcITvd4l{KEG|c3H5 NYXxdIFNUUN3ME2wMlQ5OiEQvF2= NIntfIEzOzl2MkC5OS=>
CWR22Pc NUf0SGdMSXCxcITvd4l{KEG|c3H5 NXXje|lxUUN3ME2wMlQ{QCEQvF2= MmjVNlM6PDJyOUW=
PC-3 NWPOd|IySXCxcITvd4l{KEG|c3H5 NYXjbZpZUUN3ME2xMlc2PSEQvF2= MmHWNlM6PDJyOUW=
DU145 NI[wS3hCeG:ydH;zbZMhSXO|YYm= NVXNe2QyUUN3ME2zMlUyPyEQvF2= MmnRNlM6PDJyOUW=
RC165N NXWxfmNWSXCxcITvd4l{KEG|c3H5 MVrJR|UxRTJwMEizJO69VQ>? NWLNTpNHOjN7NEKwPVU>
ARPE19 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG0OJdFVVOR MXPJR|UxRTJ2LkO4JO69VQ>? NUfTWotnOjN3M{G5NlE>
HEK293 Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPEUXNQ M2\XOmlEPTB;OD62O{DPxE1? Ml;yNlM2OzF7MkG=
KCNR M3nVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu1[HNFVVOR MnHRTWM2OD1yLkS2JO69VQ>? M4XJXlI{PTNzOUKx
SY5Y NXLrOVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvnclZFVVOR NED2d4pKSzVyPUCuN|Yh|ryP MUeyN|U{OTl{MR?=
BE2 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XTTmROW09? MnrJTWM2OD1yLkexJO69VQ>? M2K0eVI{PTNzOUKx
AS NY\zOYJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjUTXRCTE2VTx?= NIW1[G1KSzVyPUGuOVMh|ryP Mn\FNlM2OzF7MkG=
NGP MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzCV4pFVVOR M2\ZOGlEPTB;MD61OkDPxE1? MlPENlM2OzF7MkG=
IMR32 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\lSG1UVw>? MV7JR|UxRTBwNk[g{txO M1;mNVI{PTNzOUKx
LAN5 M2TkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjXXHpPTE2VTx?= NWrme2g3UUN3ME2xMlA1KM7:TR?= M{jSbVI{PTNzOUKx
RH18 M33KPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzEUXNQ MXHJR|UxRTFwNEKg{txO NIPIfYczOzV|MUmyNS=>
RH30 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfEUXNQ NF\ST4lKSzVyPUGuNlUh|ryP M3vheFI{PTNzOUKx
RH17 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\XW2VFVVOR NYrjXGlUUUN3ME2yMlUyKM7:TR?= MWqyN|U{OTl{MR?=
RH28 NV3j[4I5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PUOWROW09? MYPJR|UxRTRwMkig{txO MVKyN|U{OTl{MR?=
RH36 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Twb2ROW09? MYDJR|UxRTVwM{eg{txO Mly4NlM2OzF7MkG=
RH41 NYHwN5V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULNbmVVTE2VTx?= NXXJUVR[UUN3ME2wMlQ5KM7:TR?= NFe2fmszOzV|MUmyNS=>
RD M1TBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\WR2ROW09? MV3JR|UxRTRwM{Kg{txO MVGyN|U{OTl{MR?=
TC32 M3jjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXEUXNQ NWjifFdEUUN3ME2zMlg2KM7:TR?= NY\KU5pQOjN3M{G5NlE>
TC71 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfLN442TE2VTx?= M2PkeGlEPTB;ND6zN{DPxE1? MmTlNlM2OzF7MkG=
KCNR NY[zO5N1SXCxcITvd4l{KEG|c3H5 M3uzPVAvPS9zLkCvNk42KM7:TR?= M4nLeVI1KGh? NITubXlFVVOR MVjpcoR2[2W|IHHuJIlv[3KnYYPlJIlvKGOjc4Dhd4UhOy95IHHjeIl3cXS7 NH24S|gzOzV|MUmyNS=>
SY5Y MWTBdI9xfG:|aYOgRZN{[Xl? NFXHPIoxNjVxMT6wM|IvPSEQvF2= M3zRN|I1KGh? NEDCb29FVVOR NXPXbI9VcW6mdXPld{BidiCrbnPy[YF{\SCrbjDjZZNx[XOnIEOvO{Bi[3Srdnn0fS=> NHfXco4zOzV|MUmyNS=>
Rh18 M2ny[WFxd3C2b4Ppd{BCe3OjeR?= MWOwMlUwOS5yL{KuOUDPxE1? M1;lfVI1KGh? NFvFd25FVVOR MUjpcoR2[2W|IHHuJIlv[3KnYYPlJIlvKGOjc4Dhd4UhOy95IHHjeIl3cXS7 NYnlbpVzOjN3M{G5NlE>
TC32 NV3tT2xiSXCxcITvd4l{KEG|c3H5 MoDaNE42NzFwMD:yMlUh|ryP MWKyOEBp Mn2ySG1UVw>? NWe1NVJ2cW6mdXPld{BidiCrbnPy[YF{\SCrbjDjZZNx[XOnIEOvO{Bi[3Srdnn0fS=> NWjTWGM{OjN3M{G5NlE>
KCNR NXXKfpl2TnWwY4Tpc44hSXO|YYm= NWTYZ2hHOC53L{GuNE8zNjVxNTFOwG0> NH3jdGIzPCCq NWHGe|JXTE2VTx?= Mn;IbY5pcWKrdIOgZo91cCCnbnTv[4Vvd3W|IHPvcpN1cXS3dHn2[UBidmRiSVytOk1qdmS3Y3XkJHNVSVR|IHHjeIl3[XSrb36= MXyyN|U{OTl{MR?=
SY5Y M33teWZ2dmO2aX;uJGF{e2G7 NG\yN3UxNjVxMT6wM|IvPS93IN88US=> NFHoWoszPCCq MUfEUXNQ NWDWfWJycW6qaXLpeJMh[m:2aDDlcoRw\2Wwb4XzJINwdnO2aYT1eIl3\SCjbnSgTWwuPi2rbnT1Z4VlKFOWQWSzJIFkfGm4YYTpc44> MnTpNlM2OzF7MkG=
Rh18 NI\ye3NHfW6ldHnvckBCe3OjeR?= MUGwMlUwOS5yL{KuOU82KM7:TR?= M2KzZ|I1KGh? MojxSG1UVw>? NX7DcoF2cW6qaXLpeJMh[m:2aDDlcoRw\2Wwb4XzJINwdnO2aYT1eIl3\SCjbnSgTWwuPi2rbnT1Z4VlKFOWQWSzJIFkfGm4YYTpc44> NH;iW3czOzV|MUmyNS=>
TC32 MmnqSpVv[3Srb36gRZN{[Xl? M3rGWlAvPS9zLkCvNk42NzVizszN MV[yOEBp NGD5eVlFVVOR MlvkbY5pcWKrdIOgZo91cCCnbnTv[4Vvd3W|IHPvcpN1cXS3dHn2[UBidmRiSVytOk1qdmS3Y3XkJHNVSVR|IHHjeIl3[XSrb36= NIe4WpMzOzV|MUmyNS=>
TPC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxJOK2VQ>? NUK2WYw1OC12IHS= NWrp[JJoTE2VTx?= MVHpcohq[mm2czDj[YxtKGe{b4f0bEBi\nSncjCyJIQhfHKnYYTt[Y51 NYTOfXNCOjNyNU[0PVk>
MZ-CRC1  MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWxJOK2VQ>? NIDvNG8xNTViZB?= MWHEUXNQ MXfpcohq[mm2czDj[YxtKGe{b4f0bEBi\nSncjCxJIQhfHKnYYTt[Y51 M1;xW|I{ODV4NEm5
TT  MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\2NUDDvU1? MoXCNE01KGR? NXX6R4RETE2VTx?= M2DYOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGGodHXyJFEh\CC2cnXheI1mdnR? MXKyN|A2PjR7OR?=
TPC-1 MUnGeY5kfGmxbjDBd5NigQ>? MUWxJOK2VQ>? NXiyfnJjPzJiaB?= MlTKSG1UVw>? NFL0TZNqdmS3Y3XzJGcyKGKub3PrZYdm MWKyN|A2PjR7OR?=
MZ-CRC1  MVPGeY5kfGmxbjDBd5NigQ>? NVrMfoVwOSEEtV2= MYK3NkBp NX;PdXdqTE2VTx?= MkL4bY5lfWOnczDHNUBjdG:la3Hn[S=> NU\tSWJvOjNyNU[0PVk>
TT  NGTCbHVHfW6ldHnvckBCe3OjeR?= MmnyNUDDvU1? NEHU[ok4OiCq MXzEUXNQ MlrXbY5lfWOnczDHNUBjdG:la3Hn[S=> NYnPd2U1OjNyNU[0PVk>
MZ-CRC1  NFHQNHFCeG:ydH;zbZMhSXO|YYm= M3jiUlEhyrWP NInXZ3o1QCCq MnL6SG1UVw>? NWG5WFZmcW6mdXPld{BieG:ydH;zbZM> MUKyN|A2PjR7OR?=
TT  M370SmFxd3C2b4Ppd{BCe3OjeR?= MVWxJOK2VQ>? NIjlOIc1QCCq NFfVV4NFVVOR MXTpcoR2[2W|IHHwc5B1d3Orcx?= NXzHTpU6OjNyNU[0PVk>
HD-LM2 NHrmbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGexOWY4OuLCiXi= NXztR4d6TE2VTx?= M3;RZ2lEPTB;Nz64OFQh|ryP MlPUNlI5OjlyOUS=
L-428 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLMdZU4OuLCiXi= NILyZWJFVVOR NIW1OmtKSzVyPUeuPVQ4KM7:TR?= NIHUOGozOjh{OUC5OC=>
KM-H2 M1HXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH3O|LjiImq NF;IeZVFVVOR M{PqSWlEPTB;MT6zNFgh|ryP NIfXdYkzOjh{OUC5OC=>
L-540 MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;tSW84OuLCiXi= NXzqSYwzTE2VTx?= M{TqcGlEPTB;OD6yNVYh|ryP MlfZNlI5OjlyOUS=
HD-LM2 MofQSpVv[3Srb36gRZN{[Xl? NIXr[YUxNjFxMD61M|EwPSEQvF2= NUK0V4N5PzMkgJno Mme4SG1UVw>? NHv3dmFqdmirYnn0d{BUXEGWMzygV3RCXDViYX7kJHNVSVR4IIDoc5NxcG:{eXzheIlwdg>? Ml3KNlI5OjlyOUS=
L-428 MYrGeY5kfGmxbjDBd5NigQ>? Mn\aNE4yNzBwNT:xM|Uh|ryP M3jzOlcz6oDLaB?= NHzjWm1FVVOR NWnHN2h{cW6qaXLpeJMhW1SDVEOsJHNVSVR3IHHu[EBUXEGWNjDwbI9{eGixconsZZRqd25? NWfIb3F[OjJ6MkmwPVQ>
KM-H2 M2DXSWZ2dmO2aX;uJGF{e2G7 MnrWNE4yNzBwNT:xM|Uh|ryP NULMXWNuPzMkgJno MmjBSG1UVw>? MVPpcohq[mm2czDTWGFVOyxiU2TBWFUh[W6mIGPURXQ3KHCqb4PwbI9zgWyjdHnvci=> NVTiXJFIOjJ6MkmwPVQ>
L-540 M1\DNmZ2dmO2aX;uJGF{e2G7 M2f5e|AvOS9yLkWvNU82KM7:TR?= NFjkWWc4OuLCiXi= M4S4UGROW09? NUfOVIFrcW6qaXLpeJMhW1SDVEOsJHNVSVR3IHHu[EBUXEGWNjDwbI9{eGixconsZZRqd25? NFq4XJgzOjh{OUC5OC=>
HD-LM2 MoixRZBweHSxc3nzJGF{e2G7 MYGxM|Uh|ryP MUe3NwKBkWh? NULQN5hbTE2VTx?= MYfpcoR2[2W|IHHwc5B1d3Orcx?= MoHXNlI5OjlyOUS=
L-428 MkfzRZBweHSxc3nzJGF{e2G7 MX2xM|Uh|ryP NVS5W4E5PzMkgJno NIDL[IpFVVOR Mn;ybY5lfWOnczDhdI9xfG:|aYO= MY[yNlgzQTB7NB?=
KM-H2 NIPhO5hCeG:ydH;zbZMhSXO|YYm= NFjBd4YyNzVizszN NGHvVHI4OuLCiXi= MWPEUXNQ MXrpcoR2[2W|IHHwc5B1d3Orcx?= NUj5eXVwOjJ6MkmwPVQ>
L-540 MV3BdI9xfG:|aYOgRZN{[Xl? M2nFWlEwPSEQvF2= MnnTO|LjiImq NEiwRnJFVVOR M4jXO4lv\HWlZYOgZZBweHSxc3nz MYGyNlgzQTB7NB?=
U251-MG NHPsSo5HfW6ldHnvckBCe3OjeR?= MWWxJOK2VQ>? MYmwMVE3KGh? NEKwdVRqdmirYnn0d{Bkd26|dHn0eZRqfmViU2TBWE0{KGGwZDDKRWszKGGldHn2ZZRqd25? MoTJNlIxOjd4OUG=
U87-MG M17WO2Z2dmO2aX;uJGF{e2G7 MV2xJOK2VQ>? NWjyc2drOC1zNjDo MWfpcohq[mm2czDjc45{fGm2dYTpeoUhW1SDVD2zJIFv\CCMQVuyJIFkfGm4YYTpc44> M1nFTlIzODJ5Nkmx
4C8 NFnablJHfW6ldHnvckBCe3OjeR?= NFn3OmUyKML3TR?= MXOwMVE3KGh? NWruNXBGcW6qaXLpeJMh[2:wc4TpeJV1cX[nIGPURXQuOyCjbnSgTmFMOiCjY4TpeoF1cW:w M3nPe|IzODJ5Nkmx
U251-MG NUPES4JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxM|ExKML3TR?= NXmzTYJFOjRxNEivO|IhcA>? NWLIclR[cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGG2IHGgZ49v[2WwdILheIlwdiCxZjCxNEDDvU1? M4DiOVIzODJ5Nkmx
U87-MG NYPvN3UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j6[VEwOTBiwsXN MVuyOE81QC95MjDo M1XSbolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBifCCjIHPvcoNmdnS{YYTpc44hd2ZiMUCgxtVO M3myOlIzODJ5Nkmx
4C8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fiTFEwOTBiwsXN NXnmbG5XOjRxNEivO|IhcA>? NIHmWlNqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[XRiYTDjc45k\W62cnH0bY9vKG:oIEGwJOK2VQ>? M2LFdVIzODJ5Nkmx
U266 MVXBdI9xfG:|aYOgRZN{[Xl? NWG3dJB[OC53LUKg{txO MUm0PE84OiCq NEW4dWlqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 Mn;INlEyPjR3MUe=
Kms.11 NFXXV4hCeG:ydH;zbZMhSXO|YYm= M2mycFAvPS1{IN88US=> Mn31OFgwPzJiaB?= Mo\TbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M3L1fFIyOTZ2NUG3
8226 MX\BdI9xfG:|aYOgRZN{[Xl? MXywMlUuOiEQvF2= M4LrRlQ5Nzd{IHi= MlTQbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NXX6[JJoOjFzNkS1NVc>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 AZD1480 inhibits the STAT3 phosphorylation in an xenograft model of human solid tumors and multiple myeloma. [1] In vivo, AZD1480 inhibits the growth of subcutaneous tumors and increases survival of mice bearing intracranial glioblastoma (GBM) tumors by inhibiting STAT-3 activity, indicating that pharmacologic inhibition of the JAK/STAT-3 pathway by AZD1480 should be considered for study in the treatment of patients with GBM tumors. [3]AZD1480 blocks lung infiltration of myeloid cells and formation of pulmonary metastases in both mouse syngeneic experimental and spontaneous metastatic models. Furthermore, AZD1480 reduces angiogenesis and metastasis in a human xenograft tumor model. [4] The Jak2 inhibitor, AZD1480, suppresses the growth of human solid tumor xenografts harboring persistent Stat3 activity. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
+ 展開

kinase assays:

Inhibition studies of AZD1480 are performed using recombinant Jak1, Jak2, or Jak3 under buffer conditions of 50 mM HEPES pH 7.3, 1 mM DTT, 0.01% Tween-20, 50 mM/ml BSA, and 10 mM MgCl2. Jak3 enzyme is expressed as N-terminal GST fusion in insect cells and purified by glutathione-affinity and size-exclusion chromatographies. Enzymes are assayed in the presence of AZD1480 (10 point dose response, in triplicate, from 8.3 μM to 0.3 nM in half-log dilution steps) using 1.5 μM peptide substrate (Jak1: FITC-C6-KKHTDDGYMPMSPGVA-NH2, Jak2 and Jak3: FAM-SRCtide) and screened under their respective ATP Km (Jak1: 55 μM, Jak2: 15 μM, Jak3: 3 μM) and approximated physiological ATP concentration of 5 mM. Phosphorylated and unphosphorylated peptides are separated and quantified by a Caliper LC3000 system for calculating percent inhibition.
細胞試験: [4]
+ 展開
  • 細胞株: Renca or 786-O cells, mouse endothelial cells and splenic CD11b+/c-myeloid cells, HUVECs
  • 濃度: ~1 μM
  • 反応時間: 48 or 24 hours
  • 実験の流れ: Renca or 786-O cells are suspended in DMEM medium with 5% FBS , and seeded in 96-well plates (5×103 per well) to allow adhesion and then treated with DMSO or AZD1480 for 48 hours. Cell viability is determined by MTS assay. Absorbance at 490 nm is measured with Mikrotek Laborsysteme. Mouse endothelial cells and splenic CD11b+/c- myeloid cells are enriched from tumor-bearing mice,and cultured in 5% FBS RPMI-1640 medium. HUVECs are cultured on collagen 1–coated plates in complete medium. All cells are treated with DMSO and AZD1480 at various doses for 24 hours. Cell viability is determined by counting cell number manually. All the experiments are repeated 3 times.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Female BALB/c and athymic nude (NCR - nu/nu) mice (7–8 weeks old)
  • 製剤: AZD1480 is suspended in water supplemented with 0.5% hypromellose and 0.1% Tween 80.
  • 投薬量: Once a day at the dose of 50 mg/kg or twice daily at 30 mg/kg
  • 投与方法: Oral gavage
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.83 mM) warming
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% PEG400+0.5% Tween80+5% propylene glycol
混合させたのち直ちに使用することを推奨します。
5 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 348.77
化学式

C14H14ClFN8

CAS No. 935666-88-9
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01219543 Terminated Solid Tumour|Advanced Solid Malignancies|Child-Pugh A to B7 Advanced Hepatocellular Carcinoma|EGFR and/or ROS Mutant NSCLC|Lung Metastasis Carcinoma|Gastric Cancer AstraZeneca November 2010 Phase 1
NCT01112397 Terminated Solid Malignancies AstraZeneca April 2010 Phase 1
NCT00910728 Completed Primary Myelofibrosis (PMF)|Post-Polycythaemia Vera|Essential Thrombocythaemia Myelofibrosis AstraZeneca|University of Texas|New York City Hoffman Center|Gustave Roussy Cancer Campus Grand Paris May 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

JAKシグナル伝達経路

JAK Inhibitors with Unique Features

相関JAK製品

Tags: AZD1480を買う | AZD1480 ic50 | AZD1480供給者 | AZD1480を購入する | AZD1480費用 | AZD1480生産者 | オーダーAZD1480 | AZD1480化学構造 | AZD1480分子量 | AZD1480代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID